New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 9, 2014
16:17 EDTAEZSAeterna Zentaris announces at the market issuance program
Aeterna Zentaris announced that it has entered into an at the market issuance sales agreement with MLV & Co. under which the company may, at its discretion, from time to time during the term of the sales agreement, sell up to a maximum of 14.02M of its common shares through ATM issuances up to an aggregate amount of $15M. MLV will act as sales agent for any sales made under the ATM. The common shares will be sold at market prices prevailing at the time of the sale of common shares, and, as a result, prices may vary.
News For AEZS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
07:37 EDTAEZSAeterna Zentaris files additional patent application for zoptarelin doxorubicin
Subscribe for More Information
April 15, 2015
07:41 EDTAEZSEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
April 14, 2015
10:01 EDTAEZSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:08 EDTAEZSAeterna Zentaris upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright upgraded Aeterna Zentaris to Buy with a $1.25 price target following the successful meeting with the FDA for a new Phase 3 trial of Macrilen and a separate, thorough QT study to address issues raised by the Complete Response Letter in November 2014.
April 13, 2015
07:34 EDTAEZSAeterna Zentaris plans to conduct new Phase 3 clinical study of Macrilen
Aeterna Zentaris announced plans to conduct a new, confirmatory Phase 3 clinical study to demonstrate the efficacy of Macrilen, or macimorelin, a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency, as well as a dedicated thorough QT study to evaluate the effect of Macrilen on myocardial repolarization. This decision follows a positive and helpful meeting with the FDA regarding its New Drug Application for Macrilen. The Company's goal is to conduct a Phase 3 study that will satisfy the registration requirements of the European Medicines Agency as well as the FDA. The Company expects to receive comments from the EMA regarding the study design during a Scientific Advice Meeting in early May.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use